Natera to partner with AMAL Therapeutics on clinical trial using Signatera MRD test
Natera will partner with AMAL Therapeutics on a clinical trial focused on stage IV colorectal cancer. This study adds to the growing number of pharmaceutical trials using Natera's Signatera™ molecular residual disease assay as a biomarker to assess treatment response. March 26, 2019